Fischer Medical Ventures Limited has filed regulatory disclosures under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations following the conversion of 60 lakh convertible warrants into equity shares worth Rs. 10.53 crores. The conversion, completed through a Board resolution dated March 31, 2026, resulted in changes to promoter shareholding patterns requiring mandatory SAST disclosures.

Warrant Conversion and Allotment Details

The Board of Directors approved the allotment through a Circular Resolution, converting 60,00,000 convertible warrants into an equal number of equity shares. The conversion was executed at an issue price of Rs. 23.40 per share, representing a premium of Rs. 22.40 over the face value of Re. 1 per share.

SEBI SAST Disclosure Requirements

The warrant conversion triggered mandatory disclosures under Regulation 29(2) of SEBI SAST Regulations as it resulted in substantial changes to promoter shareholding. Mr. Shankar Varadharajan, the sole allottee, filed the required disclosures with BSE Limited and National Stock Exchange of India Limited.

Impact on Share Capital Structure

The conversion increased the company's paid-up equity share capital from Rs. 64.85 crores to Rs. 65.45 crores, divided into equity shares of Re. 1 each. The total diluted share capital, considering outstanding convertible securities, stands at Rs. 69.87 crores.

Regulatory Compliance

Fischer Medical Ventures disclosed this development in compliance with Regulation 30 of SEBI LODR Regulations and filed SAST disclosures as required under Regulation 29(2). The company informed both stock exchanges about this material development, ensuring full regulatory compliance. The conversion represents a preferential allotment mode of acquisition, strengthening the promoter group's stake while providing substantial capital infusion to the company.

Fischer medical ventures Limited has announced a key management appointment following its Board of Directors meeting held on March 24, 2026. The company has appointed Mr. Balaji Gandla as Company Secretary and Compliance Officer, marking an important addition to its leadership team.

Board Meeting Outcomes

The Board of Directors approved the appointment during their meeting on March 24, 2026, which was conducted from 11:10 AM (IST) to 12:20 PM (IST). The appointment was made pursuant to Section 203 of the Companies Act, 2013 and Regulation 6 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Professional Background

Mr. Balaji Gandla brings substantial expertise to his new role. He is a qualified Company Secretary and an Associate Member of the Institute of Company Secretaries of India (ICSI). His educational background includes a Bachelor of Commerce degree from the University of Madras, Chennai.

Key Qualifications and Experience

• Over a decade of professional experience in corporate governance
• Specialization in Secretarial Compliance and Regulatory Affairs
• Proven track record in managing end-to-end secretarial and compliance functions
• Experience with both listed and unlisted companies
• Expertise in liaison and correspondence with regulatory authorities including ROC, SEBI, BSE, and NSE

Dual Responsibilities

In addition to his role at Fischer Medical Ventures Limited, Mr. Gandla will simultaneously serve as Company Secretary of the company's wholly owned subsidiary, Time Medical International Ventures (India) Private Limited, effective from the same date.

Regulatory Compliance

The appointment fulfills the company's obligations under various regulatory frameworks and demonstrates Fischer Medical Ventures Limited's commitment to maintaining robust corporate governance standards. The company has duly informed both BSE Limited and the National Stock Exchange of India Limited about this key management personnel change as required under SEBI regulations.